Black Rock Inc. Aeglea Bio Therapeutics, Inc. Transaction History

Black Rock Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$0.11 - $0.46 $13,172 - $55,085	-119,751 Reduced 18.46%	528,897 $238,000
Q1 2023 May 12, 2023	BUY	$0.29 - $0.61 $781 - $1,643	2,694 Added 0.42%	648,648 $188,000
Q4 2022 Feb 13, 2023	SELL	$0.35 - $1.54 $135,348 - $595,534	-386,711 Reduced 37.45%	645,954 $290,000
Q3 2022 Nov 14, 2022	SELL	$0.38 - $0.81 $14,036 - $29,918	-36,937 Reduced 3.45%	1,032,665 $542,000
Q2 2022 Aug 12, 2022	SELL	$0.5 - $2.66 $926,104 - $4.93 Million	-1,852,208 Reduced 63.39%	1,069,602 $540,000
Q1 2022 May 12, 2022	SELL	$1.87 - $4.77 $143,371 - $365,711	-76,669 Reduced 2.56%	2,921,810 $6.72 Million
Q4 2021 Feb 10, 2022	BUY	$3.5 - $8.42 $51,044 - $122,797	14,584 Added 0.49%	2,998,479 $14.2 Million
Q3 2021 Nov 09, 2021	SELL	$6.03 - $7.95 $723,503 - $953,872	-119,984 Reduced 3.87%	2,983,895 $23.7 Million
Q2 2021 Aug 11, 2021	BUY	$6.32 - $8.38 $19.6 Million - $26 Million	3,103,879 New	3,103,879 $21.6 Million

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.